LORTAB 5/500

Generic Name for LORTAB 5/500

Hydrocodone bitartrate 5mg, acetaminophen 500mg; scored tabs.

Legal Classification:

CIII

Pharmacological class for LORTAB 5/500

Opioid + analgesic.

Manufacturer of LORTAB 5/500

UCB Inc.

Indications for LORTAB 5/500

Moderate to moderately severe pain.

Adult dose for LORTAB 5/500

2.5/500 or 5/500: 1–2 tabs every 4–6 hrs as needed; max 8 tabs/day.

Children's dosing for LORTAB 5/500

Use Elixir.

Also:

Precautions for LORTAB 5/500

Head injury. Increased intracranial pressure. Acute abdomen. Impaired renal, hepatic, thyroid, pulmonary, or adrenocortical function. GI or GU obstruction. Asthma. Drug abusers. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for LORTAB 5/500

Potentiation with alcohol, CNS depressants, MAOIs, tricyclic antidepressants, anticholinergics.

Adverse Reactions for LORTAB 5/500

Dizziness, CNS depression, respiratory depression, GI upset, constipation, urinary retention; hepatotoxicity (overdosage).

How is LORTAB 5/500 supplied?

Tabs 2.5/500—100
5/500, 7.5/500, 10/500—100, 500
Elixir—pt

Related Disease:

Pain, general~narcotics

Related Resources

FDA launches Web page of disposal instructions for select medicines

October 14, 2009

The FDA has launched a Web page for consumers with information on how to dispose of certain drugs, including several high-potency opioids and other selected controlled substances.

FDA halts marketing of unapproved codeine sulfate tablets

October 14, 2009

The FDA has warned four companies that they must stop marketing unapproved codeine sulfate tablets, an opioid analgesic indicated for the treatment of pain.

Onsolis available soon for breakthrough cancer pain

October 08, 2009

BioDelivery Sciences announced that Onsolis (fentanyl buccal soluble film) will be made available by Meda next week for the management of breakthrough pain in patients ≥18 years of age with cancer who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

FDA reviews NDA for Exalgo for chronic pain

September 23, 2009

Covidien, Neuromed Pharmaceuticals, and CombinatoRx announced that the FDA has heard presentations and public testimony and discussed the New Drug Application (NDA) submitted for Exalgo (hydromorphone HCl) extended release tablets for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

Embeda available for moderate to severe chronic pain

September 21, 2009

King Pharmaceuticals has made available Embeda (morphine sulfate and naltrexone HCl extended-release capsules), a long-acting opioid analgesic, for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.